Meibomian gland dysfunction refers to obstruction or dysfunction of the meibomian glands. It leads to changes in the composition or quantity of the meibomian gland secretions which are critical for maintaining a stable, smooth tear film over the outer surface of the eye. Advances in the diagnosis and treatment of dry eye disease along with a rise in the aging population have propelled the growth of the meibomian gland dysfunction market in the U.S.

The US meibomian gland dysfunction market is estimated to be valued at US$ 260 million in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the U.S. Meibomian gland dysfunction are Johnson & Johnson Vision, Novartis, Excelcare, Abbot, and Shire. Johnson & Johnson Vision has a strong presence in the meibomian gland dysfunction market with its portfolio of dry eye treatment products such as Systane and Refresh.

The growing awareness regarding treatment options for dry eye disease along with increasing recognition of U.S. Meibomian Gland Dysfunction Market Size  as a major cause of dry eye presents significant growth opportunities for players in this market. Various clinical trials are being conducted to develop advanced therapeutics for blocking the obstruction and restore the normal functionality of meibomian glands.

Major players are focusing on expanding their market presence through acquisitions and strategic collaborations with eye care professionals. For instance, in 2021, Abbot acquired Alcon to broaden its product portfolio in ophthalmology and vision care. This acquisition enabled Alcon to leverage Abbot’s global commercial infrastructure to reach more patients suffering from meibomian gland dysfunction.

Market Drivers

The increasing prevalence of dry eye disease is a major driver propelling the growth of the meibomian gland dysfunction market in the U.S. According to surveys, approximately 16-18% of adults above 50 years of age and 30% above 65 years of age suffer from dry eye disease. Moreover, excessive screen time due to increased digitalization has exacerbated the symptoms of dry eye further. Rising awareness about the available treatment options and growing focus on eye health are some other factors fueling the demand for meibomian gland dysfunction therapies in the U.S.

Get more insights on: - U.S. Meibomian Gland Dysfunction Market

For Enhanced Understanding, Dive into the Report in the Language that Connects with You:-

• French
• German
• Italian
• Russian
• Japanese
• Chinese
• Korean
• Portuguese